Rasburicase Injection Suppliers & Bulk Manufacturers

Available Forms: IV infusion

Available Strengths: 7.5 mg/15 mL vial

Reference Brands: Elitek(US)

Category: Oncology Cancer Care

Rasburicase Injection is available in IV infusion and strengths such as 7.5 mg/15 mL vial. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Rasburicase Injection is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Rasburicase Injection can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Rasburicase Injection 7.5 mg/15 mL is a critical treatment for tumor lysis syndrome (TLS), commonly associated with hematologic cancers like leukemia and lymphoma. By converting uric acid into allantoin, Rasburicase reduces the risk of kidney damage caused by high uric acid levels. Approved in both the U.S. and EU, Elitek (brand name in the U.S.) is supplied as a sterile IV solution for infusion. Rasburicase is essential for B2B pharmaceutical distribution, supporting oncology care centers, hospitals, and clinics with essential treatment for high-risk cancer patients undergoing chemotherapy.